Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521572 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16690101 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2521573 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2549985 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2512431 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 1.00 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19821287 | 0.95 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147408-A1 | (R,RP)-ISOMER OF 2'-FLUORO-6'-METHYLENE CARBOCYCLIC ADENOSINE MONOPHOSPHATE PRODRUG, AND USE THEREOF | IMMUNODESIGNERS CO., LTD. (KR) | 2024-07-11 | — | — | WO | disclosed |
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | MERCK SHARP & DOHME CORP. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180111954-A1 | PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | IDENIX PHARMACEUTICALS LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | IDENIX PHARMACEUTICALS LLC (US) | 2017-08-31 | — | — | US | disclosed |
| WO-2017019581-A1 | PROCESS FOR MAKING PHOSPHORUS-CONTAINING NUCLEOSIDE PRODRUG COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016181313-A1 | A PROCESS FOR THE PREPARATION OF SOFOSBUVIR INTERMEDIATES & ITS POLYMORPH | LUPIN LIMITED (IN) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016160646-A1 | PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160271162-A1 | D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | IDENIX PHARMACUETICALS, LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271162-A1 | D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | IDENIX PHARMACUETICALS, LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160113956-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2016-04-28 | — | — | US | disclosed |
| US-20160113956-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | UNIVERSITE DE MONTPELLIER (FR) | 2016-04-28 | — | — | US | disclosed |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | UNIVERSITE DE MONTPELLIER (FR) | 2016-01-07 | — | — | US | disclosed |
| US-20140271547-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140271547-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246198-A1 | Process for Making Nucleoside Phosphoramidate Compounds | PNP, NUDT1, NUDT14 | BTN3A1 4161/4885CYP3A4 418/4885CYP2C9 308/4885 |
| US-20170275327-A1 | SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ADH1A, ADH1C, ADH5 | BTN3A1 2751/4885CYP3A4 352/4885CYP2C9 843/4885 |
| US-20180111954-A1 | PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS | PNP, NUDT1, RNGTT | BTN3A1 2834/4885CYP3A4 1804/4885CYP2C9 402/4885 |
| US-10251903-B2 | Process for making nucleoside phosphoramidate compounds | PNP, NUDT1, NUDT14 | BTN3A1 4161/4885CYP3A4 418/4885CYP2C9 308/4885 |
| US-20160113956-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | PNP, RNGTT, NSUN2 | BTN3A1 2902/4885CYP3A4 4062/4885CYP2C9 3258/4885 |
| US-20140271547-A1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | PNP, RNGTT, NSUN2 | BTN3A1 2902/4885CYP3A4 4062/4885CYP2C9 3258/4885 |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | AADAT, BCAT1, BCAT2 | BTN3A1 2388/4885CYP3A4 3762/4885CYP2C9 3241/4885 |
| US-20160271162-A1 | D-ALANINE PHOSPHORAMIDE PRONUCLEOTIDES OF 2'-METHYL 2'-FLURO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV | PNP, RNMT, ADAR | BTN3A1 4143/4885CYP3A4 3672/4885CYP2C9 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.